

**Antibiotic Algorithm for Neutropenic Patients**  
 Adult Hematology, Blood & Marrow Transplant, and Cellular Therapy and  
 Antimicrobial Stewardship Programs  
 Approved by P+T 5.14.2019  
 Updated 9.17.2024

<sup>1</sup>If at any point in the algorithm patient becomes unstable and needs ICU-level care, return to this step.

<sup>2</sup>Considerations for anaerobic coverage and addition of metronidazole to cefepime  
 1) Intra-abdominal infection  
 2) Typhilitis

<sup>3</sup>If recent bloodstream infection with a retained central line, antibiotic coverage should include an agent active against the prior blood culture isolate. In patients with recent (< 90 days) clinical cultures with drug-resistant organisms, empirical therapy should typically include coverage for these organisms.

<sup>4</sup>Refer to the UCSF Adult Beta-lactam Allergy Guideline if listed allergy is present  
 For patients on Aztreonam, vancomycin should be included for empiric therapy given lack of gram positive/strep coverage for aztreonam

<sup>5</sup>Patients on renal replacement therapy are at risk for cefepime neurotoxicity. Pay attention to appropriate dosing. Piperacillin/tazobactam is an alternative.

1) D/C antifungal  
 2) Cont cefepime  
 3) Additional fever work-up  
 4) Transplant ID consult?

